Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review)

Blinatumomab in Pediatric Acute Lymphoblastic Leukemia—From Salvage to First Line Therapy (A Systematic Review)

Acute lymphoblastic leukemia is by far the most common malignancy in children, and new immunotherapeutic approaches will clearly change the way we treat our patients in future years. Blinatumomab is a bispecific T-cell-engaging antibody indicated for the treatment of relapsed/refractory acute lympho...

Full description

Bibliographic Details
Main Authors:	Manon Queudeville, Martin Ebinger
Format:	Article
Language:	English
Published:	MDPI AG 2021-06-01
Series:	Journal of Clinical Medicine
Subjects:	acute lymphoblastic leukemia immunotherapy bispecific T-cell engager (BiTE)
Online Access:	https://www.mdpi.com/2077-0383/10/12/2544

Similar Items

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
by: Max S. Topp, et al.
Published: (2021-04-01)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
by: Virginie Nägele, et al.
Published: (2017-05-01)

Blinatumomab, a bispecific anti-CD19/CD3 BiTE antibody for the treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
by: Lindsey eHoffman, et al.
Published: (2014-03-01)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
by: Margaux Lejeune, et al.
Published: (2020-05-01)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
by: Le Jeune C, et al.
Published: (2016-02-01)

Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study
by: Hongsheng Zhou, et al.
Published: (2022-12-01)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016-08-01)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
by: Hagop M. Kantarjian, et al.
Published: (2021-11-01)

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
by: Franquiz MJ, et al.
Published: (2020-02-01)

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
by: Daniele Caracciolo, et al.
Published: (2023-01-01)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
by: Joshua D Freedman, et al.
Published: (2017-08-01)

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer
by: Caterina Riillo, et al.
Published: (2023-05-01)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
by: Roa Alsajjan, et al.
Published: (2023-09-01)

Blinatumomab Redirects Donor Lymphocytes against CD19<sup>+</sup> Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation
by: Antonella Mancusi, et al.
Published: (2023-11-01)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
by: Cecily Allen, et al.
Published: (2021-05-01)

Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
by: Maciej Kujawski, et al.
Published: (2019-09-01)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
by: Katarzyna Pawinska-Wasikowska, et al.
Published: (2022-01-01)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
by: Hathaway L, et al.
Published: (2018-10-01)

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
by: Nicola Stefano Fracchiolla, et al.
Published: (2023-09-01)

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
by: E. V. Glukhanyuk, et al.
Published: (2019-01-01)

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
by: E. V. Glukhanyuk, et al.
Published: (2018-01-01)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
by: Jae‐Ho Yoon, et al.
Published: (2019-12-01)

Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration
by: Han-Yu Cao, et al.
Published: (2023-04-01)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
by: Sandrine Niyongere, et al.
Published: (2020-06-01)

Pediatric Acute Lymphoblastic Leukemia Emerging Therapies—From Pathway to Target
by: Anca Viorica Ivanov, et al.
Published: (2023-02-01)

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
by: Rebecca Epperly, et al.
Published: (2020-02-01)

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells
by: Caterina Riillo, et al.
Published: (2022-06-01)

Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma
by: Masuho Saburi, et al.
Published: (2024-01-01)

The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
by: Maria Maddalena Marrapodi, et al.
Published: (2022-07-01)

Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
by: Ying Wu, et al.
Published: (2022-10-01)

Design and Production of Bispecific Antibodies
by: Qiong Wang, et al.
Published: (2019-08-01)

Pancytopenia - (?) An obstacle in the diagnosis and outcome of pediatric acute lymphoblastic leukemia
by: Shruti Raja, et al.
Published: (2015-01-01)

Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy
by: Patrycja Śliwa-Tytko, et al.
Published: (2022-05-01)

Corrigendum: Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
by: Ying Wu, et al.
Published: (2022-12-01)

Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia
by: Chana L. Glasser, et al.
Published: (2023-07-01)

Emerging Immunotherapy for Acute Myeloid Leukemia
by: Rikako Tabata, et al.
Published: (2021-02-01)

Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy
by: Hweixian Leong Penny, et al.
Published: (2023-10-01)

STAGE-DEPENDENT IMMUNOPATHOGENETIC FEATURES OF ACUTE NONLYMPHOBLASTIC AND ACUTE LYMPHOBLASTIC LEUKEMIA
by: O. V. Smirnova, et al.
Published: (2014-07-01)

Renal involvement at diagnosis of pediatric acute lymphoblastic leukemia
by: Mayerly Prada-Rico, et al.
Published: (2020-04-01)

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
by: Alexandra Semchenkova, et al.
Published: (2022-04-01)